Patents Assigned to Tianjin Hemay Oncology Pharmaceutical Co., Ltd.
  • Patent number: 10294260
    Abstract: Disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, W, n are defined as in the present application. Also disclosed is a method for treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound and a salt thereof according to the present application possess good anticancer and/or antitumor activity, and good water solubility and stability, as well as good tolerance in animal bodies. Also disclosed is a process for preparing a compound represented by formula (I) of the present application.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: May 21, 2019
    Assignee: TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD.
    Inventors: Hesheng Zhang, Aihong Huo, Zhenzhong Li
  • Patent number: 10246443
    Abstract: Disclosed is a compound of formula I, a stereoisomer thereof, a cis-trans-isomer thereof, a tautomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, a solvate thereof or a prodrug thereof, wherein R1, R2, R3 and R4 are each as defined in the present application.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: April 2, 2019
    Assignee: TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD.
    Inventors: Hesheng Zhang, Yingwei Chen, Qingchao He
  • Patent number: 9840494
    Abstract: Disclosed are N-[4-(3-chloro-4-fluorophenylamino)-7-(2-methoxyethoxy) quinazolin-6-yl]-2 -[1-(2-methoxyethyl)piperidin-4-ylidene]acetamide and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: December 12, 2017
    Assignee: Tianjin Hemay Oncology Pharmaceutical Co., Ltd.
    Inventors: Hesheng Zhang, Guanghuai Zeng, Yingwei Chen
  • Patent number: 9676724
    Abstract: Disclosed is a compound of formula I, a stereoisomer thereof, a cis-trans-isomer thereof, a tautomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, a solvate thereof or a prodrug thereof, wherein R1, R2, R3 and R4 are each as defined in the present application.
    Type: Grant
    Filed: October 12, 2015
    Date of Patent: June 13, 2017
    Assignee: Tianjin Hemay Oncology Pharmaceutical Co., Ltd.
    Inventors: Hesheng Zhang, Yingwei Chen, Qingchao He
  • Patent number: 9670242
    Abstract: Disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, W, n are defined as in the present application. Also disclosed is a method for treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound and a salt thereof according to the present application possess good anticancer and/or antitumor activity, and good water solubility and stability, as well as good tolerance in animal bodies. Also disclosed is a process for preparing a compound represented by formula (I) of the present application, comprising reacting a compound represented by formula (II) with a compound represented by formula (III) in the presence of a condensation agent to obtain a compound represented by formula (I).
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: June 6, 2017
    Assignee: Tianjin Hemay Oncology Pharmaceutical Co., Ltd.
    Inventors: Hesheng Zhang, Aihong Huo, Zhenzhong Li